Virnext and VirPath are proud to announce that the French Patent Office INPI France has granted its patent FR 3 0819 789 B1 for production of viral vaccines. 2022-09-04

The invention relates to the use of the DuckCelt®17 cell line (ECACC 09070703) and method for producing the Live-Attenuated human metapneumovirus-based vaccine platform METAVAC®.

DuckCelt®-17 has been acquired by Vaxxel, a spin-off of the VirPath laboratory and Virnext. An exclusive worldwide license has been grant to Vaxxel for the use of METAVAC®.

This achievement is issued from a very fruitful collaboration with Dr. Guy Boivin’s team LVMC at the Centre de recherche du CHU de Québec-Université Laval, Transgene and our team. This work was supported by ANR (Agence nationale de la recherche), ANRT – Association Nationale de la Recherche et de la Technologie, Région Auvergne-Rhône-Alpes, Consulat général de France à Québec, Université Claude Bernard Lyon 1 EZUS Lyon Lyon Ingénierie Projet, PULSALYS, INSERM Institut national de la santé et de la recherche médicale and CNRS – Centre national de la recherche scientifique.